Evidence map›Paper›PMID 42129518›Full record

ArticleNPJ precision oncology2026

First-in-human study of FLT3 CAR-T cell therapy for relapsed acute myeloid leukemia.

Xiaojin Wu, Gao Lu, Lei Tian, Suning Chen, Michael A Caligiuri, Jianhua Yu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xiaojin WuThe First Affiliated Hospital of Soochow University, Suzhou, China.
Gao LuThe First Affiliated Hospital of Soochow University, Suzhou, China.
Lei TianDivision of Hematology & Oncology, Department of Medicine, School of Medicine, University of California, Irvine, CA, USA.
Suning ChenThe First Affiliated Hospital of Soochow University, Suzhou, China.
Michael A CaligiuriDepartment of Hematology and Hematopoietic Cell Transplantation, and the Hematologic Malignancies Research Institute, City of Hope National Medical Center, Los Angeles, CA, USA. mcaligiuri@coh.org.
Jianhua YuDivision of Hematology & Oncology, Department of Medicine, School of Medicine, University of California, Irvine, CA, USA. jianhuay@uci.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this first-in-human open-label study, autologous FLT3 CAR-T cells were delivered to two patients with relapsed and refractory FLT3

Identifiers

PMID42129518
PMCPMC13402607

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.